Exegiline

Exegiline Pharma is an Israeli biotechnology company focused on developing multifunctional therapies for neurodegenerative disorders, specifically Alzheimer's disease and dementia. The company's lead candidate, MT-031, is a novel oral small molecule designed to provide symptomatic relief and neuroprotection by combining the pharmacophores of rivastigmine and rasagiline. MT-031 functions as a triple inhibitor, targeting acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and monoamine oxidase A (MAO-A). Founded by renowned neuropharmacologist Prof. Moussa Youdim, the company operates as a spin-off from Youdim Pharmaceuticals. Exegiline aims to address the high unmet need in the Alzheimer's market by offering a single-drug solution that enhances cognition while potentially treating comorbid depression and providing neurorestorative effects.